Rankings
▼
Calendar
AKBA Q1 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$62M
+18.0% YoY
Gross Profit
$30M
49.2% margin
Operating Income
-$58M
-94.8% margin
Net Income
-$62M
-101.2% margin
EPS (Diluted)
$-0.35
QoQ Revenue Growth
+7.0%
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$535M
Total Liabilities
$509M
Stockholders' Equity
$26M
Cash & Equivalents
$175M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$62M
$52M
+18.0%
Gross Profit
$30M
$18M
+71.5%
Operating Income
-$58M
-$65M
+9.9%
Net Income
-$62M
-$70M
+10.3%
Revenue Segments
Product
$41M
67%
License Collaboration And Other Revenue
$20M
33%
← FY 2022
All Quarters
Q2 2022 →